Ross Feller Casey attorney Brian J. McCormick, Jr., was featured in a front page Legal Intelligencer story about future litigation involving the anticoagulant drug Xarelto.
McCormick, one of the nation’s leading pharmaceutical mass tort lawyers, told the legal journal that the drug “does have mass-tort potential, it’s a blockbuster drug. Thousands, if not tens of thousands of patients have taken it.”
He explained that although the U.S. Food and Drug Administration approved Xarelto relatively recently, in 2011, the drug already has had about $1 billion in sales.
“These new anticoagulants are really taking over the market. You can see the amount of ... advertising (manufacturer) Janssen is doing to push Xarelto,” McCormick said.
Xarelto (rivaroxaban) been linked to severe internal bleeding, gastrointestinal hemorrhaging, strokes and other serious side effects.
McCormick added that Ross Feller Casey has received Xarelto claims from across the country and that the firm is “talking to experts and investigating each individual claim, as well as the theory in general, although I think the theory is pretty safe now.”
To learn more about the Xarelto attorneys at Ross Feller Casey, go to www.rossfellercasey.com/practice-areas/xarelto-lawsuit/